English | Español

Janssen Biotech, Inc.
Nicholas Gueguen | Aug 17, 2017

FDA gives Imbruvica go-ahead to aid patients with chronic graft versus host disease
Jamie Barrand | Mar 9, 2016

FDA approves Imbruvica as first-line therapy for chronic lymphocytic leukemia
Jamie Barrand | Sep 17, 2015

Janssen's multiple myeloma drug accepted for FDA priority review

Trending
+ Pharmaceuticals
Patient Daily | Jun 30, 2025

PhRMA public affairs senior director on 340B program: 'PBMs took $140 billion in rebates and fees, driving up American medicine costs'
+ Pharmaceuticals
Patient Daily | Jul 1, 2025

PhRMA chief public affairs officer on 340B drug pricing: ‘Lowering drug prices for U.S. patients starts by reining in middlemen’
+ Pharmaceuticals
Patient Daily | Jul 1, 2025

American Lung Association launches campaign for World Bronchiectasis Day
+ Pharmaceuticals
Patient Daily | Jul 1, 2025

Coalition warns against potential impact of H.R. 1 on patient healthcare access